Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alexion Pharmaceuticals ( ALXN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.2%. By the end of trading, Alexion Pharmaceuticals fell $1.83 (-1.3%) to $140.75 on average volume. Throughout the day, 1,249,150 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,085,300 shares. The stock ranged in price between $140.12-$142.98 after having opened the day at $140.64 as compared to the previous trading day's close of $142.58. Other companies within the Health Care sector that declined today were: IsoRay ( ISR), down 14.4%, Ocera Therapeutics ( OCRX), down 12.4%, ImmunoCellular Therapeutics ( IMUC), down 9.7% and iBio ( IBIO), down 9.4%.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $27.4 billion and is part of the drugs industry. The company has a P/E ratio of 78.9, above the S&P 500 P/E ratio of 17.7. Shares are up 5.1% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Mast Therapeutics ( MSTX), up 43.2%, Pro-Dex ( PDEX), up 41.7%, DARA Biosciences ( DARA), up 21.6% and Atossa Genetics ( ATOS), up 18.0% , were all gainers within the health care sector with Shire ( SHPG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%